He Miaomiao, Qiu Jie, Bai Yang, Wang Yan, Hu Mei, Chen Guangzhi
Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Health Management Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Cardiovasc Med. 2021 Oct 15;8:695247. doi: 10.3389/fcvm.2021.695247. eCollection 2021.
Hypertrophic cardiomyopathy is an inherited cardiovascular disease, and 70% of patients have left ventricular outflow tract obstruction. Ventricular septal myectomy has been the gold standard treatment for most patients with refractory symptoms. Due to higher mortality associated with medical facilities with less experience, alcohol septal ablation has been accepted as an alternative to conventional surgical myectomy. It offers lower all-cause in-hospital complications and mortality, which could be potentially more preferable for patients with serious comorbidities. In recent years, radiofrequency ablation, providing another option with reproducibility and a low risk of permanent atrioventricular block, has become an effective invasive treatment to relieve left ventricular outflow tract obstruction. Moreover, substantial progress has been made in gene therapy for hypertrophic cardiomyopathy. The principal objective of this review is to present recent advances in non-pharmaceutical interventions in hypertrophic cardiomyopathy.
肥厚型心肌病是一种遗传性心血管疾病，70%的患者存在左心室流出道梗阻。室间隔心肌切除术一直是大多数有难治性症状患者的金标准治疗方法。由于经验较少的医疗机构相关死亡率较高，酒精间隔消融术已被视为传统手术心肌切除术的替代方法。它具有较低的全因院内并发症和死亡率，对于有严重合并症的患者可能更可取。近年来，射频消融术提供了另一种具有可重复性且永久性房室传导阻滞风险低的选择，已成为缓解左心室流出道梗阻的有效侵入性治疗方法。此外，肥厚型心肌病的基因治疗也取得了实质性进展。本综述的主要目的是介绍肥厚型心肌病非药物干预的最新进展。
